Your Dose of Cannabis Education
Your Dose of Cannabis Education
Only have a minute but want to Learn something every day™? Sign up to receive Your Dose of Cannabis Education, bringing featured content from our course library right to your inbox each day.
Your Dose of Cannabis Education is based on data from the studies and reviews published in the current peer-reviewed medical journals. Whether you are a healthcare provider, patient, caregiver, an individual working in the healthcare sector, or just a curious person, you can benefit from Your Dose of Cannabis Education.
Wake up every morning and get your dose of unbiased evidence-based cannabis education!
Share:
2026-02-19
The initiation of a federal review to potentially reschedule cannabis under the Controlled Substances Act represents a pivotal regulatory step. What changes to cannabis policy would take place if cannabis were to be rescheduled?
Rescheduling cannabis may reduce barriers to research, improve product standardization, clarify regulatory oversight, and reduce certain federal tax restrictions. In turn, these changes may positively affect clinician education, patient counseling, pharmacovigilance, and evidence-based decision-making. Importantly, rescheduling cannabis under the Controlled Substances Act would NOT legalize cannabis. Rescheduling only changes a substance’s placement within the federal scheduling framework. Cannabis would remain regulated and controlled, subject to federal oversight by the DEA, FDA, and other agencies. Congressional Research Service. (n.d.). Cannabis and the Controlled Substances Act. https://crsreports.congress.gov
Controlled Substances Act, 21 U.S.C. §§ 801–971 (1970).
Drug Enforcement Administration. (n.d.). Schedules of controlled substances. U.S. Department of Justice. https://www.dea.gov/drug-information/drug-scheduling
U.S. Department of Health and Human Services. (2023). Basis for the recommendation to reschedule marijuana. https://aspe.hhs.gov/reports/marijuana-rescheduling-recommendation
U.S. Department of Justice, Drug Enforcement Administration. (2024). Schedules of controlled substances; rescheduling of marijuana (Proposed rule). Federal Register. https://www.federalregister.gov
U.S. Food and Drug Administration. (n.d.). FDA and cannabis: Research and drug approval process. https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process
2026-02-18
Chronic pain is consistently the most common reason for consuming medical cannabis. What percentage of chronic pain patients in states with legal cannabis programs cite pain as the reason for cannabis use?
About 30% of individuals suffering with chronic pain in states with a regulated cannabis program report using medicinal cannabis products.Cooper, Z. D. (2025). Defining the safety and efficacy of cannabis for chronic pain: Novel approaches and reframing objectives. Annals of Internal Medicine. Advance online publication. https://doi.org/10.7326/ANNALS-25-04734
2026-02-17
What does "scromiting" mean?
The term scromiting is a portmanteau of “screaming” and “vomiting” and is used to convey the severity and intensity of hyperemesis. (It is not a distinct medical condition). Scromiting is most commonly reported in patients with cannabinoid hyperemesis syndrome (CHS). The Cleveland Clinic https://my.clevelandclinic.org/health/diseases/21665-cannabis-hyperemesis-syndrome?utm
2026-02-13
Cannabinoids can be administered transdermally. Compare CBD's skin permeability to that of THC's.
CBD’s skin permeability is ~ 10x greater than that of THC. Factors affecting transdermal absorption include local blood flow and skin permeability as well as other factors. Simei, J. L. Q., Souza, J. D. R., Pedrazzi, J. F., Guimarães, F. S., Campos, A. C., Zuardi, A., Hallak, J. E. C., & Crippa, J. A. S. (2024). Research and Clinical Practice Involving the Use of Cannabis Products, with Emphasis on Cannabidiol: A Narrative Review. Pharmaceuticals, 17(12), 1644. https://doi.org/10.3390/ph17121644
2026-02-12
THC and some other cannabinoids lower intra-ocular pressure (IOP). Why aren't cannabinoids typically useful for treating glaucoma?
There are a few reasons why cannabinoids aren't typically useful for treating glaucoma: 1.) They have a short duration of action (approximately 3-4 hours) 2.) Cannabinoids may lower systemic blood pressure and therefore may impair optic nerve perfusion 3.) THC has psychoactive effects which may not be well tolerated by elderly patients (a majority of glaucoma patients are elderly). Of note, "the American Glaucoma Society has stated that medical marijuana is not an acceptable treatment option for glaucoma." Adamek, A. J., Hussein, M. A., Abdulkarim, I., Orengo-Nania, S., & Sheheitli, H. (2025). An assessment of the prevalence of cannabis use in eye clinic patients and its implications on glaucoma diagnosis and management. International Ophthalmology, 45(1), 484. https://doi.org/10.1007/s10792-025-03846-2 and Joshi, N., Mariam, H., & Kamath, A. (2024). Cannabinoids for the treatment of glaucoma: A review. Medical Cannabis and Cannabinoids, 7(1), 183–192. https://doi.org/10.1159/000538482
Learn something every day™ in your 
feed…
Our courses
CBD in Clinical Care V2
A Nationally Approved CME/CE Medical Marijuana Course V2
Cannabis Essentials CME/CE Bundle
New to TheAnswerPage? There’s lots we’d like to share with you and we don’t want you to miss a thing! Be sure to register today for “Your Dose of Cannabis Education” emails where you’ll gain valuable insights in small doses that fit your schedule and also be provided direct access to the archived daily content.